Immunohistochemistry reliably detects ALK rearrangements in patients with advanced non-small-cell lung cancer

Virchows Archiv

Volumn 463, Issue 4, 2013, Pages 583-591

  Han, Xiao Hong ^a   Zhang, Ning Ning ^a   Ma, Li ^a   Lin, Dong Mei ^a   Hao, Xue Zhi ^a   Liu, Yu Tao ^a   Wang, Lin ^a   Liu, Peng ^a   Yuan, Zheng ^a   Li, Dan ^a   Lin, Hua ^a   Sun, Yan ^a   Shi, Yuan Kai ^a  

^a PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

Anaplastic lymphoma kinase; EML4 ALK; Fluorescence in situ hybridization; Immunohistochemistry; Non small cell lung cancer; qRT PCR

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CRIZOTINIB; ECHINODERM MICROTUBULE ASSOCIATED PROTEIN LIKE 4; EPIDERMAL GROWTH FACTOR RECEPTOR; MICROTUBULE ASSOCIATED PROTEIN; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; ARTICLE; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FUSION GENE; GENE MUTATION; GENE REARRANGEMENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; LUNG CANCER; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MOLECULARLY TARGETED THERAPY; PATIENT SELECTION; PREDICTIVE VALUE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SMOKING;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENE REARRANGEMENT; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; MALE; MIDDLE AGED; ONCOGENE PROTEINS, FUSION; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR PROTEIN-TYROSINE KINASES; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY;

EID: 84885581991     PISSN: 09456317     EISSN: 14322307     Source Type: Journal    
DOI: 10.1007/s00428-013-1472-7     Document Type: Article

References (34)

1. Kamangar F, Dores GM, Anderson WF (2006) Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24:2137-2150
2. Arora A, Scholar EM (2005) Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther 315:971-979
3. Vijayalakshmi R, Krishnamurthy A (2011) Targetable «driver» mutations in non small cell lung cancer. Indian J Surg Oncol 2:178-188
4. Lam DC (2012) Clinical testing for Molecular targets for personalized treatment in lung cancer. Respirology 18:233-237
5. Soda M, Choi YL, Enomoto M et al (2007) Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448:561-566
6. Choi YL, Takeuchi K, Soda M et al (2008) Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. Cancer Res 68:4971-4976
7. Shaw AT, Yeap BY, Mino-Kenudson M et al (2009) Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 27:4247-4253
8. Camidge DR, Kono SA, Flacco A et al (2010) Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. Clin Cancer Res 16:5581-5590
9. Zhang XC, Zhang S, Yang XN et al (2010) Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression. Mol Cancer 9:188
10. Wallander ML, Geiersbach KB, Tripp SR et al (2012) Comparison of reverse transcription-polymerase chain reaction, immunohistochemistry, and fluorescence in situ hybridization methodologies for detection of echinoderm microtubule-associated proteinlike 4-anaplastic lymphoma kinase fusion-positive non-small cell lung carcinoma: implications for optimal clinical testing. Arch Pathol Lab Med 136:796-803
11. Gandhi L, Janne PA (2012) Crizotinib for ALK-rearranged non-small cell lung cancer: a new targeted therapy for a new target. Clin Cancer Res 18:3737-3742
12. Inamura K, Takeuchi K, Togashi Y et al (2009) EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Mod Pathol 22:508-515
13. Boland JM, Erdogan S, Vasmatzis G et al (2009) Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas. Hum Pathol 40:1152-1158
14. Tiseo M, Gelsomino F, Boggiani D et al (2011) EGFR and EML4-ALK gene mutations in NSCLC: a case report of erlotinib-resistant patient with both concomitant mutations. Lung Cancer 71:241-243
15. Koh Y, Kim DW, Kim TM et al (2011) Clinicopathologic characteristics and outcomes of patients with anaplastic lymphoma kinase-positive advanced pulmonary adenocarcinoma: suggestion for an effective screening strategy for these tumors. J Thorac Oncol 6:905-912
16. Travis WD, Brambilla E, Noguchi M et al (2011) International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 6:244-285
17. Yi ES, Boland JM, Maleszewski JJ et al (2011) Correlation of IHC and FISH for ALK gene rearrangement in non-small cell lung carcinoma: IHC score algorithm for FISH. J Thorac Oncol 6:459-465
18. McLeer-Florin A, Moro-Sibilot D, Melis A et al (2012) Dual IHC and FISH testing for ALK gene rearrangement in lung adenocarcinomas in a routine practice: a French study. J Thorac Oncol 7:348-354
19. Rodig SJ, Shapiro GI (2010) Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases. Curr Opin Investig Drugs 11:1477-1490
20. Sasaki T, Janne PA (2011) New strategies for treatment of ALK-rearranged non-small cell lung cancers. Clin Cancer Res 17:7213-7218
21. Chihara D, Suzuki R (2011) More on crizotinib. N Engl J Med 364:776-777, author reply 778
22. Riely GJ, Chaft JE, Ladanyi M et al (2011) Incorporation of crizotinib into the NCCN guidelines. J Natl Compr Canc Netw 9:1328-1330
23. Mino-Kenudson M, Chirieac LR, Law K et al (2010) A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin Cancer Res 16:1561-1571
24. Martelli MP, Sozzi G, Hernandez L et al (2009) EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. Am J Pathol 174:661-670
25. Park HS, Lee JK, Kim DW et al (2012) Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients. Lung Cancer 77:288-292
26. Soda M, Isobe K, Inoue A et al (2012) A prospective PCR-based screening for the EML4-ALK oncogene in non-small cell lung cancer. Clin Cancer Res 18:5682-5689
27. Just PA, Cazes A, Audebourg A et al (2012) Histologic subtypes, immunohistochemistry, FISH or molecular screening for the accurate diagnosis of ALK-rearrangement in lung cancer: a comprehensive study of Caucasian non-smokers. Lung Cancer 76:309-315
28. Yang T, Liu H, Chen J (2012) EML4-ALK Fusion Gene in Lung Cancer and Its Biological Function. Zhongguo Fei Ai Za Zhi 15:112-116
29. Heuckmann JM, Balke-Want H, Malchers F et al (2012) Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants. Clin Cancer Res 18:4682-4690
30. Zhang YG, Jin ML, Li L et al (2013) Evaluation of ALK rearrangement in Chinese non-small cell lung cancer using FISH, immunohistochemistry, and real-time quantitative RT- PCR on paraffin-embedded tissues. PLoS One 8:e64821
31. Rodig SJ, Mino-Kenudson M, Dacic S et al (2009) Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res 15:5216-5223
32. Wu SG, Kuo YW, Chang YL et al (2012) EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wild-type EGFR. J Thorac Oncol 7:98-104
33. Wang Z, Zhang X, Bai H et al (2012) EML4-ALK rearrangement and its clinical significance in Chinese patients with advanced non-small cell lung cancer. Oncology 83:248-256
34. Kuo YW, Wu SG, Ho CC et al (2010) Good response to gefitinib in lung adenocarcinoma harboring coexisting EML4-ALK fusion gene and EGFR mutation. J Thorac Onco l 5:2039-2040